Patents matching “treatment”

US 9770427

Antiviral treatments

BioCryst Pharmaceuticals, Inc. · Granted Sep 26, 2017 · Expires Sep 21, 2037

US 9771327

Compounds and methods for the treatment of cystic fibrosis

Flatley Discovery Lab, LLC · Granted Sep 26, 2017 · Expires Sep 21, 2037

US 9763974

Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase

GALECTIN THERAPEUTICS, INC. · Granted Sep 19, 2017 · Expires Sep 14, 2037

US 9765340

RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders

Arrowhead Pharmaceuticals, Inc. · Granted Sep 19, 2017 · Expires Sep 14, 2037

US 9765337

Phosphoribosyl pyrophosphate synthetase 2 (PRPS2) as a therapeutic target in cancer treatment

The Regents of the University of California · Granted Sep 19, 2017 · Expires Sep 14, 2037

US 9764001

Target for diagnosis and treatment of diabetes and cardiovascular diseases

The Regents of the University of California · Granted Sep 19, 2017 · Expires Sep 14, 2037

US 9765053

Methods of treatment using selective 5-HT2A inverse agonists

ACADIA Pharmaceuticals Inc. · Granted Sep 19, 2017 · Expires Sep 14, 2037

US 9765142

TEM8 antibodies and their use in treatment and detection of tumors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 19, 2017 · Expires Sep 14, 2037

US 9757407

Treatment of viral infections by modulation of host cell metabolic pathways

THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Sep 12, 2017 · Expires Sep 7, 2037

US 9757366

Methods for the treatment of parkinson's disease psychosis using pimavanserin

ACADIA Pharmaceuticals Inc. · Granted Sep 12, 2017 · Expires Sep 7, 2037

US 9750724

Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases

MEREO BIOPHARMA 2 LIMITED · Granted Sep 5, 2017 · Expires Aug 31, 2037

US 9752147

RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions

Arrowhead Pharmaceuticals, Inc. · Granted Sep 5, 2017 · Expires Aug 31, 2037

US 9745576

RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders

BIOMARIN TECHNOLOGIES B.V. · Granted Aug 29, 2017 · Expires Aug 24, 2037

US 9744126

Controlled release corticosteroid compositions and methods for the treatment of otic disorders

The Regents of the University of California · Granted Aug 29, 2017 · Expires Aug 24, 2037

US 9744235

Treatment of cardiovascular disorders with targeted nanoparticles

The Board of Regents of the University of Oklahoma · Granted Aug 29, 2017 · Expires Aug 24, 2037

US 9744169

Compounds for treatment of fibrosis diseases

Curegenix, Inc. · Granted Aug 29, 2017 · Expires Aug 24, 2037

US 9744159

Methods of treatment Rett syndrome

OVID THERAPEUTICS INC. · Granted Aug 29, 2017 · Expires Aug 24, 2037

US 9737533

1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders

Addex Pharma, S.A. · Granted Aug 22, 2017 · Expires Aug 17, 2037

US 9737478

Treatment of malaria

National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), The United States of America NIH Division of Extramural Inventions and Technology Resources (DEITR) · Granted Aug 22, 2017 · Expires Aug 17, 2037

US 9730910

Treatment of circadian rhythm disorders

VANDA PHARMACEUTICALS INC. · Granted Aug 15, 2017 · Expires Aug 10, 2037

US 9730930

Treatment for vitiligo

Rigel Pharmaceuticals, Inc. · Granted Aug 15, 2017 · Expires Aug 10, 2037

US 9730962

Modalities for the treatment of degenerative diseases of the retina

Astellas Institute for Regenerative Medicine · Granted Aug 15, 2017 · Expires Aug 10, 2037

US 9730954

miRNAs as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers

The Board of Regents of the University of Texas System · Granted Aug 15, 2017 · Expires Aug 10, 2037

US 9731011

Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma

EnGeneIC Molecular Delivery Pty Ltd · Granted Aug 15, 2017 · Expires Aug 10, 2037